Journal of Hepatology
Volume 51, Issue 5 , Pages 890-897 , November 2009

Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma

  • Jaw-Ching Wu

      Affiliations

    • Department of Medical Research and Education, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming University School of Medicine, 201 Shih-Pai Road, Taipei 112, Taiwan
    • Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 2 28712121x3218; fax: +886 2 28745074.
    • These authors contributed equally to this work.
    • ,
  • Yi-Hsiang Huang

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • These authors contributed equally to this work.
    • ,
  • Gar-Yang Chau

      Affiliations

    • Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
    • Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • These authors contributed equally to this work.
    • ,
  • Chien-Wei Su

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Chung-Ru Lai

      Affiliations

    • Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • ,
  • Pui-Ching Lee

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • ,
  • Teh-Ia Huo

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • I-Jane Sheen

      Affiliations

    • Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Shou-Dong Lee

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Wing-Yiu Lui

      Affiliations

    • Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
    • Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan

Received 28 February 2009 ,Revised 1 July 2009 ,Accepted 2 July 2009.

References 

  1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–1763
  2. Llovet JM, Bruix J. Novel advancement in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48(Suppl. 1):S20–S37
  3. Huo TI, Lin HC, Hsia CY, Wu JC, Lee PC, Chi CW, et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol. 2007;102:1920–1930
  4. Huang YH, Chen CH, Chang TT, Chen SC, Wang SY, Lee PC, et al. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int. 2004;24:419–424
  5. Lopez PM, Villanueva A, Llovet JM. Systemic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535–1547
  6. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcomes in hepatocellular carcinoma. N Eng J Med. 2008;359:1995–2004
  7. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–207
  8. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–235
  9. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908–1916
  10. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49:589–594
  11. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 1994;198:489–503
  12. Hoofnagle JH, Doo E, Liang J, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056–1075
  13. Huang YH, Wu JC, Chang TT, Sheen IJ, Lee PC, Huo TI, et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat. 2003;10:277–284
  14. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;135:1625–1635
  15. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118:554–559
  16. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122:1756–1762
  17. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315–1341
  18. Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177–182
  19. Yang HI, Yeh SH, Chen PJ, Iioeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:1134–1143
  20. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol. 1994;68:8102–8110
  21. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol. 1996;70:5845–5851
  22. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology. 2003;124:327–334
  23. Yuen MF, Tanaka Y, Mizokami M, Yuen JC, Wong DK, Yuan HJ, et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogen. 2004;25:1593–1598
  24. Chen YJ, Yeh SH, Chen JT, Wu CC, Hsu MT, Tsai SF, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology. 2000;119:431–440
  25. Ishak K, Baptista A, Bianchi L, Callea F, DeGroote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  26. Wu JC, Chen CL, Hou MC, Chen TZ, Lee SD, Lo KJ. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitation of the polymerase chain reaction. Hepatology. 1994;19:836–840
  27. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature. 1989;339:237–238
  28. Mizokami M, Nakano T, Orito E, Tanaka Y, Sakugawa H, Mukaide M, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett. 1999;450:66–71
  29. Yotsumoto S, Kojima M, Shoji I, Yamamoto K, Okamoto H, Mishiro S. Fulminant hepatitis related to transmission of hepatitis B variants with precore mutations between spouses. Hepatology. 1992;16:31–35
  30. Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology. 1999;29:976–984
  31. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421–430
  32. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–1417
  33. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  34. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  35. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–1554
  36. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology. 2001;33:218–223
  37. Chan HL, Tsang SW, Liew CT, Tse CH, Wong ML, Ching JY, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol. 2002;97:406–412
  38. Huang YH, Wu JC, Chang TT, Sheen IJ, Huo TI, Lee PC, et al. Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients. J Viral Hepat. 2006;13:336–342
  39. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  40. Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg. 2005;12:16–22

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00470-X

doi: 10.1016/j.jhep.2009.07.009

Journal of Hepatology
Volume 51, Issue 5 , Pages 890-897 , November 2009

Article Tools

* Image Usage & Resolution